Onyema Greg Chido-Amajuoyi1, Dale S Mantey2, Onyinye Omega-Njemnobi3, Robert K Yu4, Sanjay Shete5. 1. Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 2. Department of Health Promotion and Behavioral Science, University of Texas School of Public Health, Austin, TX, United States. 3. Department of Epidemiology, University of Texas School of Public Health, Austin, TX, United States. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 5. Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: sshete@mdanderson.org.
Abstract
BACKGROUND: There is an established link between depression and tobacco use among adults; however, to date, research has not explored the association of use of dual/poly tobacco products with symptoms and use of medication for depression. METHODS: Data were derived from a 2018 Texas population health assessment survey (n = 2034). Multivariable logistic and multinomial regressions were used to examine for associations between self-reported symptoms of depression and use of prescription medications for depression with use of dual/poly tobacco products. RESULTS: About 20% of adults used one tobacco product, while 9.7% used two or more products. Compared to those without depressive symptoms, those with depressive symptoms had greater odds of single (aOR: 1.66, 95% CI; 1.21 - 2.29) or dual/poly (aOR: 3.09, 95% CI; 1.92 - 4.96) tobacco product use relative to non-users; and relative to single product use, those with depressive symptoms had greater odds of dual/poly tobacco product use (aOR: 2.07; 95% CI, 1.30 - 3.32). Compared to those not using medication for depression, use of medication for depression was associated with a 1.80 (95% CI: 1.15 - 2.84) greater odds of dual/poly tobacco product use relative to non-users; and a 1.91 (95% CI: 1.14 - 3.19) greater odds of dual/poly product use relative to single product users. CONCLUSIONS: Study findings call for primary care providers and psychiatrists to expand screening of individuals experiencing depressive symptoms and using medication for depression, to include assessment for dual/poly tobacco product use.
BACKGROUND: There is an established link between depression and tobacco use among adults; however, to date, research has not explored the association of use of dual/poly tobacco products with symptoms and use of medication for depression. METHODS: Data were derived from a 2018 Texas population health assessment survey (n = 2034). Multivariable logistic and multinomial regressions were used to examine for associations between self-reported symptoms of depression and use of prescription medications for depression with use of dual/poly tobacco products. RESULTS: About 20% of adults used one tobacco product, while 9.7% used two or more products. Compared to those without depressive symptoms, those with depressive symptoms had greater odds of single (aOR: 1.66, 95% CI; 1.21 - 2.29) or dual/poly (aOR: 3.09, 95% CI; 1.92 - 4.96) tobacco product use relative to non-users; and relative to single product use, those with depressive symptoms had greater odds of dual/poly tobacco product use (aOR: 2.07; 95% CI, 1.30 - 3.32). Compared to those not using medication for depression, use of medication for depression was associated with a 1.80 (95% CI: 1.15 - 2.84) greater odds of dual/poly tobacco product use relative to non-users; and a 1.91 (95% CI: 1.14 - 3.19) greater odds of dual/poly product use relative to single product users. CONCLUSIONS: Study findings call for primary care providers and psychiatrists to expand screening of individuals experiencing depressive symptoms and using medication for depression, to include assessment for dual/poly tobacco product use.
Authors: Mark W Steffen; Mohammad Hassan Murad; J Taylor Hays; Richard D Newcomb; Robin G Molella; Stephen S Cha; Philip T Hagen Journal: Popul Health Manag Date: 2014-01-29 Impact factor: 2.459
Authors: Koon K Teo; Stephanie Ounpuu; Steven Hawken; M R Pandey; Vicent Valentin; David Hunt; Rafael Diaz; Wafa Rashed; Rosario Freeman; Lixin Jiang; Xiaofei Zhang; Salim Yusuf Journal: Lancet Date: 2006-08-19 Impact factor: 79.321
Authors: Jean-G Gehricke; Sandra E Loughlin; Carol K Whalen; Steven G Potkin; James H Fallon; Larry D Jamner; James D Belluzzi; Frances M Leslie Journal: Nicotine Tob Res Date: 2007-11 Impact factor: 4.244
Authors: MeLisa R Creamer; Teresa W Wang; Stephen Babb; Karen A Cullen; Hannah Day; Gordon Willis; Ahmed Jamal; Linda Neff Journal: MMWR Morb Mortal Wkly Rep Date: 2019-11-15 Impact factor: 17.586
Authors: Sam N Cwalina; Lauren R Pacek; Jessica L Barrington-Trimis; Alayna P Tackett; Mary Ann Pentz Journal: Subst Use Misuse Date: 2021-07-29 Impact factor: 2.362